THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced it has reconstituted its Scientific Advisory Board with notable key opinion leaders in the MS field. Members of the Advisory Board include Dawn McGuire, M.D. (Chair); Doug Arnold, M.D.; Edward Fox, M.D., Ph.D; Hans-Peter Hartung, M.D.; Clyde Markowitz, M.D.; Paul O’Connor, M.D.; Chris H. Polman, M.D. and Arthur Vandenbark, Ph.D.
